罗沙司他治疗肾性贫血安全性的研究进展  

Progress of Safety of Roxadustat in the Treatment of Renal Anemia

作　　者：徐巧玲[1] 朱翊[2] 何笑荣[2] 张田 金鹏飞[2] XU Qiaoling;ZHU Yi;HE Xiaorong;ZHANG Tian;JIN Pengfei(Dept.of Pharmacy,the PLA 305 Hospital,Beijing 100034,China;Dept.of Pharmacy,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application(Beijing Hospital),Beijing 100730,China)

机构地区：[1]中国人民解放军第305医院药局,北京100034 [2]北京医院药学部,国家老年医学中心,中国医学科学院老年医学研究院,北京市药物临床风险与个体化应用评价重点实验室(北京医院),北京100730

出　　处：《中国医院用药评价与分析》2022年第6期761-764,768,共5页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：国家重点研发计划项目(No.2020YFC2008300)。

摘　　要：针对罗沙司他治疗肾性贫血的安全性问题,检索相关国内外文献,从作用机制、药动学、药效学和国内外用药安全性研究等方面进行分析。发现罗沙司他在发挥升高血红蛋白作用的同时,可能引发心血管事件、血管通路血栓形成、深静脉血栓形成、癫痫发作和严重感染等不良反应,与安慰剂或对照药相比,其存在安全性风险升高的趋势。表明罗沙司他可有效改善患者的肾性贫血症状,但仍需重点关注其引发的安全性问题。In view of the safety of roxadustat in the treatment of renal anemia,relevant domestic and foreign literature were searched and analyzed from the aspects of mechanism of action,pharmacokinetics,pharmacodynamics and drug safety research at home and abroad.It is found that while increasing hemoglobin,roxadustat may cause adverse drug reactions such as cardiovascular events,vascular access thrombosis,deep vein thrombosis,seizures and severe infections,and there is a tendency of higher safety risk compared with placebo or control drugs.It is suggested that roxadustat can effectively improve the symptoms of renal anemia in patients,yet the safety of roxadustat should be paid more attention.

关 键 词：罗沙司他 肾性贫血 安全性 不良反应 

分 类 号：R973[医药卫生—药品]